arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Summit Therapeutics Inc.

SMMT Health Care Biotechnology: Pharmaceutical Preparations
$15.55
▼ -3.4% Today
as of Oct 22, 16:52 ET
Last 30 days -15.58% Sep 14 → Oct 22
$14.33 $15.43 $16.53 $17.62 $18.72 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$15.29
High
$15.70
Low
$15.13
Volume
$4M
Avg Vol
$4M
Mkt Cap
$14.4B
P/E (TTM)
—
Beta
—
52w High
$29.23
52w Low
$12.07
Div Yield
—
Shares Out
$793M

Recent Press Releases & News last 60 days · 25 items

Oct 21 · 14:00 Zacks
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?
Oct 21 · 12:42 PR PR Newswire
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Oct 21 · 10:40 MT Newswires
Summit Therapeutics to Collaborate With ECOG-ACRIN Cancer Research Group to Test Bile Duct Cancer Drug
▸ Show all 25 press releases & news Free account →

SMMT earnings at a glance

The options market is pricing a move of about ±14.4% after the report, a range of roughly $13.32 to $17.78 from today's $15.55. Over its last 6 reports the stock rose the next day 2 times and fell 4, moving ±10.1% on average; after the most recent report on Jul 23, 2026 it moved -8.8%. That means options currently expect more movement than SMMT has typically delivered. SMMT beat the consensus EPS estimate in 2 of its last 6 reported quarters. Implied volatility is currently 89%. The share price of $15.55 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$12
$29
20% of range
Avg surprise (last 6)
-130.6%
Avg reaction (last 6)
-5.7%
33% positive
Latest IV / EM
89%
EM ±14.4% · $17 · Oct 23

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.43$-1.08$-0.72$-0.37$-0.02 Actual $-1.43Actual $-0.02Actual $-0.03Actual $-0.06Actual $-0.09Actual $-0.08Actual $-0.09Est $-0.10Actual $-0.76Est $-0.10Actual $-0.31Est $-0.14Actual $-0.29Est $-0.22Actual $-0.24Est $-0.33Actual $-0.28Est $-0.26 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258K8KJun/2026
Revenue vs Net Income Revenue Net income
$-566M$-439M$-312M$-186M$-59M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu Jul 23, 2026Jun/2026 $-0.28 $-0.26 -7.7% +65.8% -8.8% earnings
Thu Apr 30, 20268K 2026-04-30 $-0.24 $-0.33 +27.3% — -24.9% earnings
Mon Feb 23, 20268K 2026-02-23 $-0.29 $-0.22 -31.8% — +0.2% earnings
Mon Oct 20, 2025Sep/2025 $-0.31 $-0.14 -121.4% — -4.5% earnings
Mon Aug 11, 2025Jun/2025 $-0.76 $-0.10 -660.0% — -9.1% earnings
Thu May 1, 2025Mar/2025 $-0.09 $-0.10 +10.0% — +13.1% earnings
Mon Sep 30, 2024Sep 2024 $-0.08 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.09 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.06 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.03 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.02 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.43 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue———————$0
Cost of revenue————————
Gross profit————————
Operating income———————$-58M
Net income$-216M$-189M—$-232M$-566M$-63M—$-56M
EPS (diluted)$-0.28$-0.24—$-0.31$-0.76$-0.09—$-0.08

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$419M$107M$225M$239M$298M$212M$105M$94M
Inventory————————
Total current assets$721M$617M$720M$246M$309M$371M$424M$490M
Total assets$752M$648M$751M$262M$324M$384M$436M$503M
Long-term debt————————
Total liabilities$122M$102M$92M$69M$65M$39M$47M$65M
Total equity$630M$546M$659M$192M$259M$344M$389M$438M

Implied volatility — last 90 days

42%99%156%213%270% Jun 07 — IV 91% · EM ±8.5%Jun 08 — IV 84% · EM ±7.1%Jun 09 — IV 89% · EM ±6.5%Jun 10 — IV 175% · EM ±10.3%Jun 11 — IV 114% · EM ±4.8%Jun 15 — IV 78% · EM ±5.6%Jun 16 — IV 85% · EM ±5.0%Jun 17 — IV 60% · EM ±2.5%Jun 19 — IV 43% · EM ±4.7%Jun 22 — IV 61% · EM ±5.1%Jun 23 — IV 61% · EM ±4.4%Jun 24 — IV 68% · EM ±4.0%Jun 25 — IV 67% · EM ±2.8%Jun 29 — IV 98% · EM ±23.2%Jun 30 — IV 101% · EM ±23.4%Jul 01 — IV 50% · EM ±2.1%Jul 03 — IV 67% · EM ±7.5%Jul 06 — IV 109% · EM ±9.1%Jul 07 — IV 85% · EM ±6.1%Jul 08 — IV 152% · EM ±9.0%Jul 09 — IV 93% · EM ±3.9%Jul 13 — IV 98% · EM ±8.1%Jul 14 — IV 45% · EM ±3.3%Jul 15 — IV 87% · EM ±5.1%Jul 16 — IV 146% · EM ±6.1%Jul 20 — IV 241% · EM ±20.2%Jul 21 — IV 170% · EM ±12.3%Jul 22 — IV 255% · EM ±15.0%Jul 23 — IV 271% · EM ±11.3%Jul 27 — IV 91% · EM ±7.6%Jul 29 — IV 66% · EM ±3.9%Jul 30 — IV 169% · EM ±7.1%Aug 03 — IV 90% · EM ±7.6%Aug 04 — IV 105% · EM ±7.6%Aug 05 — IV 100% · EM ±5.9%Aug 06 — IV 71% · EM ±3.0%Aug 10 — IV 64% · EM ±5.4%Aug 11 — IV 109% · EM ±7.9%Aug 12 — IV 78% · EM ±4.6%Aug 17 — IV 112% · EM ±9.4%Aug 18 — IV 111% · EM ±8.0%Aug 19 — IV 103% · EM ±6.1%Aug 20 — IV 135% · EM ±5.6%Aug 24 — IV 112% · EM ±9.4%Aug 25 — IV 92% · EM ±6.6%Aug 26 — IV 95% · EM ±5.6%Aug 27 — IV 50% · EM ±2.1%Aug 31 — IV 61% · EM ±5.1%Sep 01 — IV 93% · EM ±6.7%Sep 02 — IV 83% · EM ±4.9%Sep 03 — IV 98% · EM ±4.1%Sep 07 — IV 88% · EM ±7.4%Sep 08 — IV 108% · EM ±7.8%Sep 09 — IV 113% · EM ±6.6%Sep 10 — IV 189% · EM ±7.9%Sep 14 — IV 124% · EM ±10.3%Sep 15 — IV 128% · EM ±9.3%Sep 16 — IV 196% · EM ±11.6%Sep 17 — IV 112% · EM ±4.7%Sep 21 — IV 96% · EM ±8.0%Sep 22 — IV 97% · EM ±7.0%Sep 23 — IV 108% · EM ±6.4%Sep 24 — IV 207% · EM ±8.7%Sep 28 — IV 149% · EM ±31.2%Sep 29 — IV 88% · EM ±18.0%Sep 30 — IV 101% · EM ±20.3%Oct 01 — IV 96% · EM ±18.8%Oct 02 — IV 90% · EM ±17.3%Oct 05 — IV 82% · EM ±14.6%Oct 06 — IV 99% · EM ±17.1%Oct 07 — IV 82% · EM ±13.6%Oct 08 — IV 89% · EM ±14.4%

Sector peers

ASND
Ascendis Pharma A/S
$15.0B $242.99+3.7%
CORT
Corcept Therapeutics Incorporated
$12.9B $107.50-7.7%
ELAN
Elanco Animal Health Incorporated
$11.2B $22.69-0.0%
RDY
Dr. Reddy's Laboratories Ltd
$10.2B $13.23-0.2%
NUVL
Nuvalent, Inc.
$9.8B $123.96
AXSM
Axsome Therapeutics, Inc.
$9.1B $156.07-2.2%

SMMT earnings FAQ

What is SMMT's expected move for earnings?

Options currently price a move of about ±14.4%, or $2.23 per share either way from $15.55.

How does SMMT stock usually react to earnings?

Across the last 6 reports the average next-day move was ±10.1%, up 2 times and down 4 times.

What is SMMT's implied volatility?

SMMT's at-the-money implied volatility is about 89% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in